Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 9/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | COMT | P21964 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | F12 | P00748 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5122442 | 0.98 | PRKDC (0.51) | PRKDCMTORADORA3PARP1GRM5 | |
| SCHEMBL3539918 | 0.73 | PRKDC (0.61) | PRKDCMTORPARP1MAPTRAB9A | |
| SCHEMBL11924607 | 0.73 | PRKDC (0.61) | PRKDCMTORPARP1MAPTRAB9A | |
| SCHEMBL8167826 | 0.73 | PRKDC (0.61) | PRKDCMTORPARP1MAPTRAB9A | |
| SCHEMBL10969790 | 0.72 | KDM4E (0.57) | ADORA3MAPTRAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL30050610 | 0.72 | IDO1 (0.41) | PRKDCMTORADORA3PARP1MAPT | |
| SCHEMBL877668 | 0.72 | IDO1 (0.41) | PRKDCMTORADORA3PARP1MAPT | |
| SCHEMBL12145470 | 0.71 | CYP3A4 (0.44) | PRKDCMTORPARP1MAPTRAB9A | |
| SCHEMBL1839402 | 0.71 | PRKDC (0.54) | PRKDCMTORPARP1MAPTALDH1A1 | |
| SCHEMBL1104807 | 0.71 | IDO1 (0.46) | PRKDCPARP1MAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674823-B2 | DNA-PK inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-03-09 | — | — | US | disclosed |
| EP-2138495-A1 | Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives | sanofi-aventis (FR) | 2009-12-30 | — | — | EP | disclosed |
| US-7226918-B2 | DNA-PK inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-06-05 | — | — | US | disclosed |
| US-20040192687-A1 | Dna-pk inhibitors | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2004-09-30 | — | — | US | disclosed |
| EP-0166439-B1 | 4H-pyrimido[2,1-a]isoquinolin-4-one derivatives | G.D. Searle & Co. (US) | 1990-05-09 | — | — | EP | disclosed |
| EP-0166439-B1 | 4H-pyrimido[2,1-a]isoquinolin-4-one derivatives | G.D. Searle & Co. (US) | 1990-05-09 | — | — | EP | disclosed |
| US-4661592-A | ANORECTIC AGENTS | G. D. SEARLE & CO. (US) | 1987-04-28 | — | — | US | disclosed |
| US-4661592-A | ANORECTIC AGENTS | G. D. SEARLE & CO. (US) | 1987-04-28 | — | — | US | disclosed |
| US-4661592-A | ANORECTIC AGENTS | G. D. SEARLE & CO. (US) | 1987-04-28 | — | — | US | disclosed |
| EP-0166439-A2 | 4H-pyrimido[2,1-a]isoquinolin-4-one derivatives | G.D. Searle & Co. (US) | 1986-01-02 | — | — | EP | disclosed |
| EP-0166439-A2 | 4H-pyrimido[2,1-a]isoquinolin-4-one derivatives | G.D. Searle & Co. (US) | 1986-01-02 | — | — | EP | disclosed |
| EP-0166439-A2 | 4H-pyrimido[2,1-a]isoquinolin-4-one derivatives | G.D. Searle & Co. (US) | 1986-01-02 | — | — | EP | disclosed |
| US-4127720-A | ANTIALLERGENS | BRISTOL-MYERS COMPANY (US) | 1978-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192687-A1 | Dna-pk inhibitors | ATM, CHEK1, XRCC6 | PRKDC 92/4885MTOR 803/4885ADORA3 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.